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 Abstract 
 This prospective study aimed to determine speech understanding in neurofibromatosis type 
II (NF2) patients following implantation of a MED-EL COMBI 40+ auditory brainstem implant 
(ABI). Patients (n = 32) were enrolled postsurgically. Nonauditory side effects were evaluated 
at fitting and audiological performance was determined using the Sound Effects Recognition 
Test (SERT), Monosyllable-Trochee-Polysyllable (MTP) test and open-set sentence tests. Sub-
jective benefits were determined by questionnaire. ABI activation was documented in 27 pa-
tients, 2 patients were too ill for testing and 3 patients were without any auditory perception. 
SERT and MTP outcomes under auditory-only conditions improved significantly between first 
fitting and 12-month follow-up. Open-set sentence recognition improved from 5% at first fit-
ting to 37% after 12 months. The number of active electrodes had no significant effect on 
performance. All questionnaire respondents were ‘satisfied’ to ‘very satisfied’ with their ABI. 
An ABI is an effective treatment option in NF2 patients with the potential to provide open-set 
speech recognition and subjective benefits. To our knowledge, the data presented herein is 
exceptional in terms of the open-set speech perception achieved in NF2 patients. 
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 Introduction 
 Neurofibromatosis type II (NF2) typically leads to a clinical picture dominated by neuro-
logical symptoms caused by the development of multiple benign spinal and brain tumors 
(Schwann cell tumors)  [1] . The hallmark of NF2 is the development of bilateral vestibular 
schwannomas. However, unilateral vestibular schwannomas, a family history of NF2, or any 
two of meningioma, glioma, neurofibroma, schwannoma or posterior subcapsular opacities 
are also diagnostic criteria for NF2  [2] . 
 Vestibular schwannomas involve the internal auditory canal or cerebellopontine angle 
and frequently result in severe disability and reduced life expectancy. Complete loss of 
hearing is common in the majority of bilaterally affected patients due to the destruction of the 
auditory nerve, usually resulting either from tumor growth or from treatment (by surgical 
tumor removal or radiosurgery). After surgical treatment of the tumor the hearing preser-
vation of patients, who showed useful preoperative hearing, ranges from 32 to 88%  [3–6] . 
Patients with deafness and preserved function of the cochlear nerve are good candidates for 
cochlear implantation  [7, 8] . However, in patients with complete hearing loss, following nerve 
degeneration or nerve loss by tumor destruction, an auditory brainstem implant (ABI) repre-
sents the only remaining therapeutic option to provide patients with auditory input  [9–13] . 
 Several studies indicate that ABIs are effective and safe in providing useful auditory 
sensations in most patients with NF2 who would otherwise be totally deaf  [9, 14–21] . 
However, only a minority of the patients in the aforementioned  studies achieved open-set 
speech discrimination and the speech recognition of individuals with an ABI varied consid-
erably; most patients use their ABI to facilitate lip-reading and can only recognize environ-
mental sounds  [9, 15–19, 22] . Importantly, even those with strongly limited speech recog-
nition reported being very satisfied with their implant, showing that NF2 patients can gain 
remarkable objective and subjective benefits from ABI use  [18] .
 Another factor contributing to the performance of an ABI are nonauditory side effects. 
Typically, nonauditory side effects are produced via inadvertent stimulation of the cerebellar 
flocculus, the cerebellar peduncle, the long sensory tracts or the facial nerve. It is not unusual 
for NF2 patients with an ABI to experience nonauditory sensations  [23] . Up to 42% of users 
experience them  [24, 25] and almost all of these nonauditory effects are benign, but they 
cause considerable discomfort to the individual  [23] . Nonauditory side effects are usually 
managed by selecting the configuration of the electrodes  [26] , i.e. programming out the 
stimulus. In multichannel ABIs different sites of electrode stimulation can generate different 
pitch percepts  [27] . Therefore, changes in the frequency spectrum of sounds can be coded for 
by changes in electrode activation  [27] . Consequently, deactivation of electrodes due to 
nonauditory sensations can potentially affect the performance seen in patients fitted with an 
ABI. Although reports indicate that the number of functional electrodes affects the perfor-
mance of speech recognition tests  [19, 28] , opinions regarding the existence of a correlation 
between the number of active electrodes and patient performance remain divided.
 This study aimed to determine speech understanding capabilities over time in NF2 
patients following implantation of an ABI. In particular, this paper evaluated open-set speech 
understanding and subjective benefits in NF2 patients with an ABI, who experience some 
auditory sensation, over a 1-year postactivation period. In addition, the frequency and conse-
quences of nonauditory side effects were assessed.
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 Materials and Methods 
 Patients and Inclusion Criteria 
 Between April 2001 and July 2009, 32 patients who received a MED-EL COMBI 40+ ABI were enrolled 
postsurgically in this prospective multicenter study; 16 patients were treated at Würzburg (University of 
Würzburg, Würzburg, Germany), while the remainder were treated at 6 other centers. The mean age at 
implantation was 38.4 years (range: 19.0–66.1 years). Individual subject data are shown in  table 1 . For 
inclusion in this study, subjects were 15 years or older and diagnosed with NF2. All patients gave written 
informed consent.
 All patients were implanted using the surgical procedure as described by Matthies et al.  [16] (2000), 
Behr et al.  [18] (2007) and Jackson et al.  [22] (2002); 6 participants received the MED-EL COMBI 40+ and 26 
the ABI. The ABI is a development of the COMBI 40+ offering an electronic platform, which allows a maximum 
stimulation rate of 50.760 compared to 18.180 pulses/second, which was possible with the COMBI 40+. 
Besides the electronics there is no difference between the 2 implants. Both feature a ceramic housing, offer 
the CIS+ speech-coding strategy  [29] , and comprise an electrode carrier with 13 (12 stimulation and 1 
Table 1.  Subject demographics
Subject
ID
Age at implantation Gender Side
implanted
 Number of active electrodes
years months first 
fitting
1
month
3
months
6
months
12
months
1 41 8 M R 10 10 – – –
2 34 11 F L 10 10 11 10 –
3 42 3 M R 5 4 5 5 2
4 63 7 M R 10 9 12 12 12
5 49 10 M R 12 – 12 12 12
61 42 4 F L too sick to test
7 36 5 M L 7 8 – 9 9
8 22 7 M L 7 – 8 8 8
91 48 4 F R nonuser
10 45 12 F R 12 12 9 8 8
11 23 1 M R – 7 7 7 7
12 35 12 M R 7 7 7 7 7
13 54 1 F R 12 12 12 12 12
14 27 7 F L 9 10 – 9 9
15 25 11 F R 7 7 7 12 12
16 19 3 F R 8 8 8 8 7
171 40 12 F R nonuser
18 39 12 M L 12 8 10 10 10
191 40 3 F L too sick to test
20 51 1 F L 8 8 6 6 6
211 30 2 M L nonuser
22 21 5 F R 12 12 12 – –
23 41 9 F R 7 7 – – –
24 66 11 M R 10 9 9 9 9
25 39 7 M R 8 8 – – –
26 43 4 F L 6 6 6 6 –
27 42 10 M bilateral 6 5 5 5 5
28 31 8 M L – – – – –
29 42 2 M R – – – – –
302 33 6 M R – – – – –
312 26 8 M L – 7 7 7 7
32 25 7 F R 8 8 8 8 8
 1 Not included in data analysis. 2 Revision cases.
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reference) platinum contacts partially embedded in a preshaped flat silicone paddle  [18, 22] . In addition, the 
ABI electrode features a polyester mesh to increase the stability of the electrode array on the surface of the 
cochlear nucleus.
 At the time of enrolment all subjects showed acceptable general health and mental stability. However, 
at follow-up 5 subjects could not be included in the study due to poor health, which prevented them from 
performing any tests (subjects 6 and 19), or they were excluded because they did not experience any auditory 
sensation (subjects 9, 17 and 21). Subjects 27 and 30 underwent ABI implantation a number of years earlier 
without success. Subject 27 was bilaterally implanted as a nonuser in the left ear, and was tested with the 
active right implant. Subject 26 had prior ABI experience; however, the ABI lost function following tumor 
regrowth. Likewise, subject 31 had prior ABI experience; however, trauma resulting in an implant defect led 
to implantation of a new device on the same side. 
 Device Fitting 
 All patients were fitted with the TEMPO+ BTE speech processor. In general, initial stimulation took place 
6–8 weeks after surgery and was performed during a 3-day inpatient hospitalization. In some cases an 
extended rehabilitation period after tumor removal was required and led to delayed implant activation. 
 First fitting was performed in a monitored environment such as an Intensive Care Unit. Pulse oximetry, 
continuous echocardiography and noninvasive blood pressure were monitored during the fitting process. 
Emergency resuscitation equipment and drugs were available and an Advanced Cardiac Life Support certified 
individual was present. Activation commenced with stimulation of individual electrodes. Patients were 
instructed to report any auditory and nonauditory sensations. Electrodes with clear auditory percept and no 
or negligible nonauditory side effects were selected for an initial program. 
 Following 1–2 days of listening experience and refinement of the initial program the first assessment of 
performance was conducted. Pitch ranking of the selected electrodes was attempted during first fitting; 
however, in some cases this was only possible at subsequent fitting sessions. After electrodes were balanced 
in loudness, participants were asked to name the electrodes with the highest and lowest pitches. Successive 
repetition and reordering led to a tonotopic ranking of the electrodes.
 Follow-up assessment took place at 1, 3, 6 and 12 months postactivation. During follow-up, individual 
electrode stimulation for loudness, pitch and nonauditory side effects, and speech and sound perception 
were used to optimize the program. The nature and subjective strength of nonauditory side effects deter-
mined which electrode contacts were activated in this study. Contacts were either checked repeatedly with 
regard to nonauditory side effects at follow-up or were in some instances, depending upon the nature of 
nonauditory side effects, deactivated pending a shift from nonauditory to auditory sensations that required 
the activation of those electrodes. Some nonauditory side effects often decreased in magnitude over time and, 
despite being associated with negative side effects initially, could be reactivated at a later session. Side effects 
that left the electrodes completely unusable were typically located in the leg, arm, chest or face and described 
as pain, tickling or muscle activation; these were left deactivated.
 Audiological Testing 
 For testing, subjects were seated in a sound-attenuated chamber, 1 m in front of a speaker. Recognition 
of environmental sounds was tested using the recorded test materials of the Sound Effects Recognition Test 
(SERT). This test consists of 3 different lists of 10 items each, which were offered in a closed-set procedure. 
 Speech test materials were presented in live voice at normal speech level. The order of the test condi-
tions were auditory-visual (ABI + lip-reading), auditory only (ABI) and visual only (lip-reading). The auditory-
only condition was also presented in live voice, but the speaker’s mouth was covered using a sound-trans-
parent mask. 
 To acknowledge the large variability in hearing performance, 2 tests with different levels of difficulty 
were conducted: the Monosyllable-Trochee-Polysyllable (MTP) test from the MED-EL EARS test battery 
(http://www.medel.com/data/downloads/BRIDGE/Brochures/Ears-Norms-Manual.pdf) and an open-set 
sentence test. The MTP assesses words and number of syllables recognized and consists of a closed set of 12 
words offered twice each in a random order. The open-set sentence tests employed were as follows: (1) the 
Hochmair-Schulz-Moser (Germany, n = 16); (2) the Polish Hochmair-Schulz-Moser (Poland, n = 2); (3) the 
Technical Committee on Cochlear Implant in Japan test, 2004 (Japan, n = 6); (4) the open-set sentence recog-
nition test (Hong Kong, n = 1), and (5) the Institute of Hearing Research sentence test (South Africa, n = 1). 
At each test interval, and for each of the 3 test conditions, a different list of sentences was used and the 
number of words recognized correctly counted.
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 Subjective Benefit Assessment 
 Six months after first fitting all participants were asked to complete a questionnaire specifically designed 
to assess the subjective impact of the ABI on the users. The questionnaire consisted of 7 questions assessing 
topics such as the time needed to become accustomed to the ABI, the influence of the ABI on daily life and 
listening capacity, as well as the subject’s overall impression regarding the ABI.
 Statistical Analyses 
 Descriptive statistics were used to report demographic data and baseline device fitting characteristics. 
Quantitative data are presented as mean, standard deviation and range (minimum and maximum); quali-
tative data are presented as absolute and relative frequencies. The Kolmogorov-Smirnov test was used to 
determine data distribution.
 The effects between first fitting and 12-month testing for the SERT, the closed-set MTP test and the 
open-set sentence test were examined using the nonparametric Mann-Whitney U test. To show the benefit over 
lip-reading added by the ABI, the auditory gain for open-set sentence test results was calculated by subtracting 
the mean scores obtained under visual-only conditions from those under auditory-visual conditions.  
 Outcomes of the 7-item subjective questionnaire are presented as absolute and relative frequencies. 
Missing data were not replaced but treated as ‘missing’ values. Data of participating study sites were pooled. 
To prevent a treatment-by-center interaction, each study site followed an agreed protocol. A p value <0.05 
was determined as statistically significant. IBM SPSS Statistics 19 (IBM, Armonk, N.Y., USA) was used for all 
analyses. Graphs were created in Microsoft Office Excel 2010 (http://www.microsoft.com).
 Results 
 Number of Active Electrodes and Nonauditory Side Effects 
 At first fitting an average of 8.8 ± 2.2 out of 12 available contacts were activated to provide 
auditory stimuli to the subjects ( table 1 ). None of the 27 subjects included had less than 5 
active electrodes. Over time, the number of active electrodes remained essentially stable. 
Electrode contacts were deactivated due to several reasons: (1) contacts providing no 
sensation at all; (2) contacts causing unpleasant sound sensation (sound often described as 
faint, scratchy or persistent); (3) contacts with the same pitch rank (for optimized fitting); (4) 
contacts with mixed-auditory and nonauditory sensations (if nonauditory sensations were 
not tolerated by the subject), and (5) contacts with only nonauditory responses. 
 No information was available regarding nonauditory side effects for 7 subjects (25.9%); 
8 subjects (29.6%) did not experience any nonauditory side effects. Of the remaining 12 
subjects the body location and nonauditory sensation with the number of contacts (deacti-
vated and active) causing the side effect are shown in  figure 1 . The nature of the side effect(s) 
led to deactivation in 48 out of 144 total contacts (33.3%); 11 out of 144 contacts (7.6%) were 
maintained in an active state despite subjects experiencing nonauditory sensations. Amongst 
these, 2 contacts were deactivated after the first fitting, while 9 were active throughout the 
duration of the study. 
 Sound Effect Recognition Test  
 The SERT was performed by 26 subjects in total. As shown in  figure 2 , a steady increase 
in SERT scores averaged across all data available was observed up to the 6-month test interval. 
The improvement between the first fitting scores and the 12-month test were significant
(p = 0.009, n = 11 subjects who performed the test at the first fitting and 12-month test 
interval). 
 Monosyllabic-Trochee-Polysyllabic Tests  
 The closed-set MTP test was performed by 27 subjects in total. The test was scored by 
correct identification of syllables and words under the auditory-only and auditory-visual 
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condition. In both test conditions (auditory-only and auditory-visual) the mean syllable 
scores reached test ceiling immediately after device activation (data not shown). Individual 
word scores are shown in  table 2 . 
 Under auditory-only conditions the mean correct word score across all data available 
(‘all data’ group) was 11.7 ± 6.4 words out of 24 (48.7%) at first fitting. The mean outcome 
calculated from patients who were tested at all scheduled intervals (‘complete’ group) was 
12.1 ± 6.0 words (50.4%). A steady increase in mean results was observed over the 12-month 
follow-up period for both the ‘all data’ and the ‘complete’ group. The improvement between 
first fitting scores and 12-month testing was highly significant for auditory-only word recog-
nition (Mann-Whitney U test: p < 0.001, n = 19). 
 Under the auditory-visual condition the test ceiling was reached at first fitting. Likewise, 
no statistically significant difference was observed in the auditory-visual word score between 
the first fitting and 12-month testing (Mann-Whitney U test: p = 0.106, n = 18).
 Sentence Tests 
 Sentence tests were performed by 26 subjects in the auditory-visual condition, 23 in the 
auditory-only condition and 22 in the visual-only condition. Results averaged across all 
available data under all conditions are shown in  figure 3 . A highly significant improvement 
from the first fitting to the 12-month test was observed under the auditory-only (Mann-
16.7/18.2%
33.3/7.6%
6.2/9.1%
77.1/72.7%
Head
Head
Head
Temple
Temple
Ear
Eye/eyebrow
Eye
Eye
Chin
Arm
Chest
Leg
4
8
1
1
1
2
2
4
3
2
2
4
2
48/144
1
1
3
1
1
1
2
1
11/144
Headache/knocking, pressure sensation
Dizziness
Tickling
Tactile
Pain
Twitching/tickling
Twitching/tickling
Eye movement
Blurred vision
Irritation
Unpleasant sensation
Tickling/unpleasant sensation
Twitching
Location Sensation
Number of contacts
deactivated/active
 Fig. 1. Location and frequency of nonauditory sensations experienced by patients with an ABI at first fitting 
(n = 12). 
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 Fig. 2. Environmental sound recognition performance determined by SERT in patients with an ABI after first 
fitting and 1, 3, 6 and 12 months postactivation. Boxplot whiskers depict sample minimum and maximum; 
the white square equals the mean value.  
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 Fig. 3. Open-set speech recognition as determined by sentence testing in patients with an ABI after first fit-
ting and 1, 3, 6 and 12 months postactivation. A: auditory only; V: visual only; AV: auditory-visual combined; 
Gain: AV-V. Boxplot whiskers depict sample minimum and maximum; the white square equals the mean 
value. Error bars represent standard deviation. Negative ‘Gain’ values represent patients who performed 
poorer in the combined auditory-only and visual-only conditions compared to the visual conditions. 
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Whitney U test: p < 0.001, n = 8) and the auditory-visual test conditions (p = 0.001, n = 12); no 
significant improvement was observed under visual-only test conditions (p = 0.083, n = 6). 
 Individual sentence test results under the auditory-only and auditory-visual conditions 
are shown in  table 3 . All subjects who performed the sentence test in the auditory-visual 
condition at first fitting (17 out of 26) were able to achieve at least some open-set speech 
understanding. Of the subjects available for the sentence test under auditory-visual condi-
tions at first fitting and at 12-month testing, 11 out of 12 subjects performed better at the 
12-month test interval. In the auditory-only condition 12 subjects performed the test at first 
fitting; 5 subjects achieved open-set speech understanding in this difficult test situation. After 
12 months of ABI use 19 subjects could be tested, and all but 1 achieved open-set speech 
understanding. Overall, these data illustrate the improvement and learning ability over time 
Table 2.  Individual results of MTP words (words repeated correctly) of the auditory-only and auditory-visual test conditions
Subject
ID
Auditory only  Auditory-visual
first
fitting
1
month
3
months
6
months
12
months
first 
fitting
1
month
3
months
6
months
12
months
1 – 8 6 – 17 – 15 16 – 21
2 – 14 22 16 22 – 23 24 24 24
3 4 – 1 4 7 21 – 22 22 22
4 13 21 20 22 21 – 24 23 24 24
5 – – 18 18 20 – – 23 24 24
7 20 24 24 24 23 24 24 24 24 24
8 7 17 23 21 24 24 24 24 24 24
10 12 14 21 24 24 24 24 24 24 24
11 – – – 21 22 – – – 23 24
12 14 21 19 21 21 22 23 24 24 24
13 15 13 4 16 8 24 24 24 24 24
14 14 20 18 24 20 24 24 24 24 24
15 14 16 18 19 16 22 24 24 24 24
16 6 22 13 17 21 24 22 23 24 21
18 10 17 16 21 18 22 24 24 24 24
20 0 12 10 15 20 24 24 24 24 24
22 10 24 24 – – 23 24 24 – –
23 6 9 19 – – 24 24 24 – –
24 24 24 – 24 24 22 23 – 24 24
25 11 4 – – – 24 24 – – –
26 19 19 21 21 23 24 24 24 24 24
27 11 12 18 22 22 24 24 24 24 24
28 13 17 20 18 21 24 24 24 24 24
29 18 16 18 20 23 23 23 23 24 24
301 19 15 16 16 12 24 24 24 24 24
311 – 20 19 16 21 – 24 24 24 24
32 11 14 16 21 23 23 24 24 24 24
All data group
n 21 24 24 23 24 21 24 24 23 24
Mean ± SD 11.7±6.4 15.4±5.3 16.1±6.2 17.9±4.8 19.6±4.2 23.2±1.0 23.2±2.1 23.2±2.1 23.8±0.6 23.6±1.0
Mean ± SD
complete 12.1±6.0 15.8±3.0 16.7±3.4 18.8±2.4 19.2±3.4 23.4±0.8 23.7±0.6 23.8±0.4 24.0±0.0 23.8±0.8
 Mean values ± SD are depicted for all data available (all data) and for the patients who performed the test at all test intervals 
(complete) under auditory-only (n = 17) and auditory-visual conditions (n = 16). SD = Standard deviation. 1 Revision cases.
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both on an individual and group basis. In summary, of the 19 subjects that could be tested at 
12 months, under auditory-only conditions, a mean open speech perception of 37% was 
achieved. Under audio-visual conditions at 12 months the percentage of speech perception 
achieved was 77%.
 To determine the benefit of ABI use over lip-reading alone, the auditory gain was calcu-
lated for the ‘all data’ group ( fig. 3 ). At all test intervals the auditory gain was greater than the 
auditory-only performance, i.e. the sum of the results under auditory-only and visual-only 
combined was less than the performance under auditory-visual conditions. Furthermore, the 
auditory gain increased significantly over time from the first fitting to the 12-month test (p = 
0.008). 
Table 3.  Individual sentence test results (% correct) of the auditory-only and auditory-visual test conditions
Subject
ID
Auditory only  Auditory-visual
first
fitting
1
month
3
months
6
months
12
months
fi rst
fitting
1
month
3
months
6
months
12
months
1 – 0.0 0.0 – 35.6 – 50.0 4.4 – 8.9
2 – 0.9 22.8 22.6 16.0 – 42.5 60.4 38.7 59.4
3 – – – – – 1.8 – – 8.8 –
4 12.3 19.3 0.0 31.6 1.8 70.2 89.5 82.5 78.9 63.2
5 – – 25.0 35.7 21.2 – – 26.8 48.2 21.2
7 26.4 80.2 64.2 87.7 86.8 78.3 100.0 91.5 96.2 100.0
8 – 15.1 12.3 28.3 63.4 – 34.0 69.8 91.5 98.1
10 0.0 1.9 2.8 68.3 81.1 46.2 63.2 83.0 92.5 98.1
11 – – – 69.8 79.2 – – – 100.0 100.0
12 – – 8.3 13.3 23.3 – 75.0 81.7 75.0 93.3
13 – – – – – 44.3 40.6 43.4 59.4 –
14 6.6 28.3 12.3 12.3 – 78.3 79.2 94.3 91.5 97.2
16 – – – 0.0 10.4 5.1 – – 2.8 67.0
18 – 1.7 18.3 13.3 11.7 30.0 56.7 71.7 65.0 80.0
20 – – – – – – 65.1 – 65.1 83.0
22 0.0 94.3 – – 86.8 91.5 100.0 – – –
23 0.0 0.0 7.0 – – 75.4 87.7 96.5 – –
24 3.8 65.1 – 99.1 97.2 90.6 94.3 – 98.1 100.0
25 0.0 – – – – 15.8 – – – –
26 13.2 9.4 39.6 9.4 12.3 70.8 90.6 100.0 100.0 79.2
27 – 9.6 3.8 7.5 14.2 – 65.1 87.7 91.5 87.7
28 – – 0.0 1.9 16.0 2.8 23.8 35.8 28.3 75.5
29 0.0 0.0 0.0 0.0 5.7 19.8 29.2 56.6 37.7 73.6
301 0.0 1.9 0.0 0.0 0.0 35.8 52.8 57.5 35.8 48.1
311 – 0.0 22.6 11.3 38.7 – 82.1 92.5 76.4 84.9
32 0.0 0.0 0.0 11.3 36.8 53.8 69.8 70.8 84.0 93.4
All data group
n 12 17 18 19 20 17 21 19 22 21
Mean ± SD 5.2±8.3 19.9±30.2 13.3±17.1 27.6±30.8 36.9±32.8 47.7±31.3 66.2±23.6 68.8±26.2 66.6±30.1 76.8±25.3
Mean ± SD
complete 7.4±10.3 16.1±29.1 15.2±26.0 29.8±35.0 32.1±37.6 48.6±26.2 65.5±25.6 74.4±20.0 71.0±27.5 80.8±16.9
 Mean values ± SD are depicted for all data and for the patients who performed the test at all test intervals (complete) under auditory-
only (n = 7) and auditory-visual conditions (n = 10). SD = Standard deviation. 1 Revision cases.
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 Subjective Questionnaire 
 The subjective questionnaire was completed by 16 out of 27 subjects ( table 4 ). Adjustment 
to the ABI was performed without difficulty in the majority of cases. The time needed to adjust 
to the ABI was ‘minimal’ or ‘moderate’ in 78.5% of the subjects. Accordingly, 73.3% reported 
that the adjustment to the ABI was ‘not at all’ or only ‘somewhat’ difficult for them. Only 1 
subject (6.7%) felt that the adjustment was ‘very difficult’; 50% of the subjects experienced 
‘very positive’ or ‘somewhat positive’ changes in their emotional state since wearing the ABI. 
Again, only 1 subject (6.3%) reported a ‘somewhat negative’ experience. Ratings given by the 
users of the degree of help provided by the ABI in different listening situations showed the 
biggest benefit during individual conversation, with 93.7% of patients reporting improved 
listening abilities ‘sometimes’ to ‘often’. Listening in groups was ‘sometimes’ to ‘often’ 
improved in 50.0% of users; however, 43.8% reported that they ‘hardly’ or ‘not at all’ bene-
Table 4.  Questionnaire results
n %
About how long would you say it took for you to no time 3 21.4
adjust to your ABI? hardly any time 3 21.4
moderate amount of time 5 35.7
quite some time 3 21.4
a very long time 0 0.0
How difficult was this adjustment for you? not difficult 4 26.7
somewhat difficult 7 46.6
moderately difficult 2 13.3
quite difficult 1 6.7
very difficult 1 6.7
How would you rate the changes in your emotional very positive 4 25.0
state since you began wearing an ABI? somewhat positive 4 25.0
neutral 7 43.7
somewhat negative 1 6.3
very negative 0 0.0
Has your ABI improved listening in individual not at all 0 0.0
conversation? hardly 1 6.3
sometimes 6 37.5
often 9 56.2
not applicable 0 0.0
Has your ABI improved listening in groups? not at all 2 12.5
hardly 5 31.3
sometimes 6 37.5
often 2 12.5
not applicable 1 6.3
Has your ABI improved listening in noisy not at all 4 26.7
environments? hardly 6 40.0
sometimes 3 20.0
often 1 6.7
not applicable 1 6.7
How satisfied are you in general with your ABI? very satisfied 5 33.3
fairly satisfied 6 40.0
adequately satisfied 4 26.7
hardly satisfied 0 0.0
not at all satisfied 0 0.0
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:4
6:
26
 P
M
292ORL 2013;75:282–295
 DOI: 10.1159/000350568 
 Matthies et al.: Auditory Brainstem Implantation Improves Speech Recognition in 
Neurofibromatosis Type II Patients  
www.karger.com/orl
© 2013 S. Karger AG, Basel
fitted from the ABI during group conversation. The least benefit was experienced in noisy 
environments with only 26.7% of users reporting a benefit ‘sometimes’ to ‘often’ and 66.7% 
benefitting ‘hardly’ or ‘not at all’. The questionnaire shows that, overall, 100% of patients 
were ‘adequately satisfied’ to ‘very satisfied’ with their ABI.
 Discussion 
 In patients suffering from NF2 and a complete hearing loss, following tumor growth or 
removal, use of an ABI affords them some external auditory information. The extent of infor-
mation provided is thought to facilitate lip-reading and the recognition of environmental 
sounds  [9, 16–19, 22] . However, significant functional auditory-alone speech recognition is 
not expected  [30–32] . Despite these limitations, NF2 patients with an ABI report varying 
degrees of benefit  [22, 33–37] . The data presented herein shows that patients with an ABI 
demonstrate an initial improvement in SERT following first fitting. Likewise, MTP results 
show that under auditory-only conditions identification of words is enhanced with an ABI. 
Similarly, the capacity of the patients to determine sentences under auditory-only conditions 
was improved. This effect was apparent as early as 1 month after fitting. Sentence test perfor-
mance under auditory-visual conditions was improved significantly. However, as no signif-
icant improvement in visual-only sentence testing was observed, the data in the present 
study suggests that NF2 patients can acquire benefits beyond enhanced lip-reading when 
using an ABI. This is likely to contribute to the patient’s perception of the subjective benefits 
of using an ABI.
 A period of acclimatization and learning facilitates the achievement of maximum benefit 
 [9, 35] . However, the effects of NF2 on general health also need to be considered. In the 
present study follow-up testing was frequently interrupted or abandoned on account of 
patients suffering fatigue or on account of extrinsic factors as described by Otto et al.  [9] . As 
follow-up is often perturbed by the pathological presentation of NF2, data were analyzed as 
a complete data set or following the exclusion of any individual(s) with missing data. Visual 
comparison of both data sets indicates that there is no apparent difference between the 
‘healthier’ group and the group as a whole. 
 Another health-related consequence of ABI fitting is that electrical stimulation of the 
human brainstem carries the risk of nonauditory side effects. Most ABI patients experience 
these side effects, the solution to which is simply turning the electrode off  [23] . Likewise, 
postoperative side effects of ABI activation determined the number of stimulatory electrodes 
programmed in this study. However, successful programming around the nonauditory sensa-
tions was possible in all patients included. The total number of active electrodes had no signif-
icant effect on the overall exceptional hearing performance of NF2 patients with an ABI 
presented in this study (data not shown) and the number of active electrodes over time 
appeared stable compared to the setting at first fitting. Similarly, Schmidt Goffi-Gomez et al. 
 [38] showed that the number of active electrodes was not clinically related to outcome.
 The current data clearly illustrate that with an ABI high levels of auditory performance 
were achieved in NF2 patients. NF2 patients with complete hearing loss implanted with the 
MED - EL COMBI 40+ or ABI showed an improvement in hearing performance after surgery. 
Closed-set MTP testing indicated that between the first fitting and the 12-month follow-up 
auditory-only word recognition was improved.
 Of greater importance in the present study, NF2 patients with an ABI showed a significant 
improvement in auditory recognition when tested in an open-set task, i.e. sentence tests. The 
capacity of the patients to recognize sentences under auditory-only conditions over the entire 
test period (from first fitting to 12-month follow-up) improved and, likewise, their sentence 
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test performance under auditory-visual conditions. The improvement in sentence recog-
nition was already apparent after 1 month. These data are of significant relevance because 
typically under auditory-only conditions ABI listeners are unable to recognize a significant 
amount of speech when tested in an open-set recognition task  [13] . Using sound only from 
their ABI few NF2 patients recognized up to 20% of the words in sentences  [13, 15] . The 
majority of NF2 patients recognize less than 5% of the words in sentences, even after several 
years of practice with the ABI  [13, 39] . Moreover, as test materials become more complex, e.g. 
from word tests to open-set testing, performance with the ABI is thought to decline, especially 
under auditory-only conditions  [17] . Nevison et al. indicate that although closed-set word 
identification tests show limited auditory-alone word identification, it would not be possible 
for ABI users to rely on their ABI alone. It was thought that the use of the ABI with lip-reading 
allowed the key words in conversation to be identified  [17] . In contrast, the data presented 
in this study shows clearly that a large proportion of ABI users achieve valuable open-set 
speech understanding even if they rely exclusively on auditory-only input. Of all patients 
tested (all data) in the present study, the percentage of words recognized correctly in the 
sentence test using auditory-only cues was 20% after 1 month of ABI use. At the 12-month 
test interval this increased to 37%, which accounts for a considerably larger proportion than 
reported previously in the published literature  [13, 39] . To investigate possible influencing 
factors comparative studies with a larger cohort of patients would be necessary. The current 
data is, however, substantiated with preliminary data collected in 2002 on the MED-EL ABI 
 [22] . Furthermore, the results obtained with lip-reading in conjunction with the auditory 
input improved the benefit further than under auditory-only conditions. Thus, the data 
suggests that the exceptional benefit of the COMBI 40+ or ABI is in terms of comparatively 
real-life communication. The reasons for the difference in speech outcomes in the present 
study, compared to other published studies, have yet to be determined. We suspect the placing 
electrode used in MED-EL ABI systems has an effect. Once the placing electrode has been posi-
tioned intraoperatively, electrically evoked auditory brainstem responses can be recorded 
that aid the surgeon in the correct placement of the active ABI electrode. We presume that the 
test stimulation and intraoperative recording of electric auditory brainstem response may be 
one reason for better results using the MED-EL ABI. This should be a major point of investi-
gation in future studies. 
 Moreover, the auditory gain as determined by open-set testing increased over time and 
was significantly greater after 12 months compared to the results at activation (p = 0.008). 
This suggests that the gain in speech recognition by NF2 patients with an ABI will potentially 
improve further over time. This is likely to occur due to a continued learning effect following 
ABI activation. Likewise, several authors indicate that the success of the NF2 patients with 
hearing loss in rehabilitation is most obvious upon long-term follow-up  [20, 40] .
 However, some patients with an ABI in the present study showed a complete lack of 
improvement, whilst others managed a significant degree of rehabilitation. Other authors 
also report a significant degree of interindividual variability in the performance of NF2 
patients with an ABI  [13, 19] . Similarly, the study by Nevison et al.  [17] in 2002 indicated that 
although most subjects did not achieve satisfactory auditory-alone open-set speech under-
standing, 2 patients of 17 tested received sufficient benefit from the ABI to an extent that 
allowed them to participate in conversation without the visual cues of lip-reading. The wide 
variation may in part be contributed to difficulties with follow-up, as mentioned briefly 
earlier. Frequently, the follow-up of patients with NF2 is perturbed due to changes in the 
status of the patient’s health; in addition to nonauditory side effects, the most common of 
which are dizziness and ipsilateral tingling  [41–43] .
 Despite these difficulties, the subjective benefits in patients with an ABI determined via 
questionnaire in the present study showed that overall all of the respondents were ‘adequately’ 
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to ‘very satisfied’ with their ABI even after 6 months of follow-up. The majority reported 
improved listening ability ‘sometimes’ to ‘often’ in individual conversations. However, 
listening in noisy environments continued to pose a problem, as a case study of ABI use had 
previously indicated  [20] . Similarly, listening in groups was ‘sometimes’ to ‘not at all’ improved 
in most cases. According to Colletti et al.  [41] , perceptual performance in ABI recipients can 
often vary considerably depending on the duration of the disease, the treatment of the disease 
and the number of active electrodes, in addition to their spatial configuration. However, in 
the context of the present study the data illustrates a relatively consistent improvement 
following auditory brainstem implantation with an overall satisfaction from ‘adequately’ to 
‘very satisfied’, demonstrating the importance of providing some auditory input to patients 
deafened due to NF2. 
 In conclusion, the data presented herein indicate that NF2 patients with an ABI generally 
show improved closed-set speech recognition and, moreover, that patients show exceptional 
open-set sentence recognition. The acquisition of open-set speech recognition goes beyond 
the benefits achieved by lip-reading alone. Taking this into account and the young age of most 
NF2 sufferers, in addition to the unfortunate progressiveness of the disease, the capacity to 
restore some of the patient’s hearing is of significant relevance, particularly in terms of quality 
of life.
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